| Literature DB >> 34806151 |
Muskan Pandey1, Archana Bhati1, Kumari Priya1, K K Sharma2, Barkha Singhal3.
Abstract
The health catastrophe originated by COVID-19 pandemic construed profound impact on a global scale. However, a plethora of research studies corroborated convincing evidence conferring severity of infection of SARS-CoV-2 with the aberrant gut microbiome that strongly speculated its importance for development of novel therapeutic modalities. The intense exploration of probiotics has been envisaged to promote the healthy growth of the host, and restore intestinal microecological balance through various metabolic and physiological processes. The demystifying effect of probiotics cannot be defied, but there exists a strong skepticism related to their safety and efficacy. Therefore, molecular signature of probiotics termed as "postbiotics" are of paramount importance and there is continuous surge of utilizing postbiotics for enhancing health benefits, but little is explicit about their antiviral effects. Therefore, it is worth considering their prospective role in post-COVID regime that pave the way for exploring the pastoral vistas of postbiotics. Based on previous research investigations, the present article advocates prospective role of postbiotics in alleviating the health burden of viral infections, especially SARS-CoV-2. The article also posits current challenges and proposes a futuristic model describing the concept of "precision postbiotics" for effective therapeutic and preventive interventions that can be used for management of this deadly disease.Entities:
Keywords: Dysbiosis; Gut microbiome; Gut-brain axis; Postbiotics; Probiotics; SARS-CoV-2
Mesh:
Substances:
Year: 2021 PMID: 34806151 PMCID: PMC8606251 DOI: 10.1007/s12602-021-09875-4
Source DB: PubMed Journal: Probiotics Antimicrob Proteins ISSN: 1867-1306 Impact factor: 5.265
Summary of clinical trials utilizing various probiotics for the prevention and treatment of COVID-19 registered clinical trials (https://clinicaltrials.gov/; https://clinicaltrials.gov/ct2/who)
| S.No | Status | NCT no | Title for study | Study type | Participants | Intervention | Location | References |
|---|---|---|---|---|---|---|---|---|
| 1 | Recruiting | NCT04390477 | Study to evaluate the effect of a probiotic in COVID-19 | Interventional | 40 | Dietary supplement: probiotic | Spain | |
| 2 | Not yet recruiting | NCT04621071 | Efficacy of probiotics in reducing duration and symptoms of COVID-19 | Interventional | 84 | Dietary supplement: probiotics (2 strains 10*10^9 UFC) Dietary supplement: Placebo (potato starch and magnesium stearate) | Canada | |
| 3 | Not yet recruiting | NCT04877704 | Symprove (probiotic) as an add-on to COVID-19 Management | Interventional | 60 | Other: symprove (probiotic) Other: placebo | UK | |
| 4 | Completed | NCT04458519 | Efficacy of intranasal probiotic treatment to reduce severity of symptoms in COVID19 infection | Interventional | 40 | Other: probiorinse Other: saline solution | Canada | |
| 5 | Recruiting | NCT04666116 | Changes in viral load in COVID-19 after probiotics | Interventional | 96 | Dietary supplement: dietary supplementation in patients with COVID disease admitted to hospital | Spain | |
| 6 | Active, not recruiting | NCT04756466 | Effect of the consumption of a | Interventional | 314 | Dietary supplement: placebo Dietary supplement: | Spain | |
| 7 | Not yet recruiting | NCT04907877 | Interventional | 300 | Other: dietary supplement | Ukraine | ||
| 8 | Recruiting | NCT04847349 | Live microbials to boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) immunity clinical trial | Interventional | 45 | Dietary supplement: OL-1, standard dose Dietary supplement: OL-1, high dose Dietary supplement: placebo | USA | |
| 9 | Recruiting | NCT04366180 | Evaluation of the probiotic | Interventional | 314 | Dietary supplement: probiotic Dietary supplement: control | Spain | |
| 10 | Recruiting | NCT04734886 | The effect of probiotic supplementation on SARS-CoV-2 antibody response after COVID-19 | Interventional | 400 | Dietary supplement: Dietary supplement: placebo + vitamin D | Sweden | |
| 11 | Recruiting | NCT04366089 | Oxygen-ozone as adjuvant treatment in early control of COVID-19 progression and modulation of the gut microbial flora (PROBIOZOVID) | Interventional | 152 | Other: oxygen-ozone therapy, probiotic supplementation, and standard of care Dietary supplement: SivoMixx (200 billion) Drug: azithromycin Drug: hydroxychloroquine | Italy | |
| 12 | Completed | NCT04517422 | Efficacy of | Interventional | 300 | Dietary supplement: probiotics Other: placebo | Mexico | |
| 13 | Recruiting | NCT04462627 | Reduction of COVID 19 transmission to healthcare professionals | Interventional | 500 | •Diagnostic test: blood group determination •Diagnostic test: antibody titration •Dietary supplement: probiotic | Belgium | |
| 14 | Completed | NCT04854941 | Efficacy of probiotics in the treatment of hospitalized patients with novel coronavirus I infection | Interventional | 200 | Other: probiotics | Russian Federation | |
| 15 | Recruiting | NCT04813718 | Post COVID-19 Syndrome and the Gut-lung Axis | Interventional | 20 enrolled | Dietary supplement: Omni-biotic Pro Vi 5 (Pre- and probiotic) Placebo | Austria | |
| 16 | Recruiting | NCT04798677 | Efficacy and tolerability of ABBC1 in volunteers receiving the influenza or Covid-19 vaccine | Interventional | 90 | Dietary supplement: ABBC1 immunoessential Dietary Supplement: placebo | Spain | |
| 17 | Recruiting | NCT04399252 | Effect of Lactobacillus on the microbiome of household contacts exposed to COVID-19 | Interventional | 1132 | Dietary Supplement: | USA | |
| 18 | Not yet recruiting | NCT04884776 | Modulation of gut microbiota to enhance health and immunity | Interventional | 484 | Dietary supplement: microbiome immunity formula Dietary supplement: active placebo | Hong Kong | |
| 19 | Not yet recruiting | NCT04507867 | Effect of a Nss to reduce complications in patients with Covid-19 and comorbidities in stage III | Interventional | 240 | Dietary supplement: nutritional support system (NSS) Other: Control | — | |
| 20 | Recruiting | NCT04420676 | Synbiotic Therapy of gastrointestinal symptoms during Covid-19 infection | Interventional | 108 | Dietary supplement: Omnibiotic AAD Dietary supplement: placebo | Austria |
Fig. 1Conception, timeline development, and applications of postbiotics
Application of various postbiotics in alleviation of various diseases
| S. NO | Probiotic organisms | Paraprobiotic/postbiotic components | Disease application | Model | References |
|---|---|---|---|---|---|
| 1 | Lactobacillus plantarum JLK0142 | Exopolysaccharides | EPS also increased IgA concentrations in the intestinal mucosa and stimulated lymphocyte proliferation | Mice model | [ |
| 2 | Peptide | Inhibited the late stages of HSV-1 and HSV-2 replication | Vero cells | [ | |
| 3 | A two-peptide bacteriocin | Inhibited the growth of | Model of the distal colon | [ | |
| 4 | Nisin F | Prevented respiratory tract and subcutaneous skin infections instigated by S. aureus | Mice model | [ | |
| 5 | Non-protein cell wall component | Reduced the replication of HSV-2 | Vero cells | [ | |
| 6 | Peptidoglycans | Inhibit the release of inflammatory cytokines in models of LPS-induced macrophage-like cells | HT-29 cells | [ | |
| 7 | Heat killed | Increase of paracellular permeability, restoration of tight junction function and membrane integrity, and modulating cytokine gene expression | CacoGoblet cells | [ | |
| 8 | Exopolysaccharides | Improve the anti-inflammatory response through the modulation of cytokine IL-8 production | AGS cells (adherent human gastric adenocarcinoma epithelial cell line) | [ | |
| 9 | Cell-free supernatants (CFS) | MMP-9 and ZO-1 as targets via which secreted factors from probiotic bacteria | Human colon carcinoma cell line HCT-116 | [ | |
| 10 | Peptidoglycan | Immunomodulatory properties | Mice model | [ | |
| 11 | Heat inactivated | Reduction of human rhinovirus infection | Healthy subjects aged 18 to 65 years | [ | |
| 12 | Cell-free supernatant | Antifungal activity influence-inhibited aflatoxin B1 and ochratoxin A production | MRS broth | [ | |
| 13 | Cell-free supernatant | Enhance ruminal papillae growth, immune status (increase of IL-6 mRNA and decrease of IL-1β, IL-10, TNF mRNA expression), and gastrointestinal health | Twelve newly weaned male lambs | [ | |
| 14 | Bacteriocin | Reduces production of viral proteins in infected cells | Primary chick embryo fibroblasts cell cultures (CEF) | [ | |
| 15 | Bacteriocin (subtilisin) | Disrupts late infectious stages of both HSV type 1 | Vero cell cultures | [ | |
| 16 | Enterocin CRL35 | Found to lower glycoprotein gD synthesis, disrupting a slightly earlier step in the infectious cycle of HSV compared to subtilosin | Monkey kidney Vero cells | [ | |
| 17 | Bacteriocins | Bacteriocins could inhibit the growth of | Fish | [ | |
| 18 | Peptides | Antimicrobial peptides produced by | Turkey digestive tract | [ | |
| 19 | Heat inactivated | Immunostimulatory effects | [ | ||
| 20 | Culture supernatant | Inhibition of immune cell inflammation and protect the host from pathobionts and enteric pathogens and had protective effects against colitis | Mice model | [ | |
| 21 | Heat-killed fermentate | Increase on sociability and lower baseline corticosterone (stress hormone) levels | Healthy mice | [ | |
| 22 | Heat killed | Increase the hemocyte density | Invertebrate model | [ | |
| 23 | Secreted protein | Treatment of intestinal barrier dysfunction-related diseases | Rat model | [ | |
| 24 | Paraprobiotic | As increased the production of monocyte chemoattractant protein-1 (MCP-1) and T CD4 + CD44 + lymphocytes | Murine systemic toxoplasmosis model | [ | |
| 25 | Peptidoglycans | Reduced susceptibility to influenza infection, reduced inflammatory cell infiltrates in the lungs, and enhanced the speed of viral clearance | Influenza infection rodent model | [ | |
| 26 | Butyric acid | Improve epithelial barrier integrity and management in inflammatory bowel diseases (IBD) and Crohn’s disease (CD) | Caco-2 model | [ | |
| 27 | Heat killed | Anti-allergic and antiviral effects by activating Th1 immune response and protective immune system | Mice model | [ | |
| 28 | Cell-free soluble factors | The protective effect against enteropathogenic | Caco-2 cellular model | [ | |
| 29 | Exopolysaccharides | EPSs such as kefiran are potential candidates for preventing cardiovascular diseases | Rabbit model | [ | |
| 30 | Probiotics | Lactobacilli, such as LGG and TMC0356, might protect a host animal against Flu infection | Mouse model | [ | |
| 31 | SLPs | Increasing their transepithelial resistance (TER) and down-regulating their permeability | Caco-2 cells | [ | |
| 32 | Lipoteichoic acid | Anti-inflammatory responses | IPEC-J2 cell line | [ | |
| 33 | p40 and p75 | p40 and p75 induce a significant reduction in the H2O2-induced redistribution of occludin and ZO-1 from the intercellular junctions | Caco-2, T84, and HT29 cell | [ | |
| 34 | LTA | LTA-induced antiviral activity is primarily due to the induction of cathelicidin | Mouse model | [ | |
| 35 | SCFAs | Alternative for controlling Salmonella infection and maintaining metabolic homeostasis | Piglets | [ | |
| 36 | Pili | Promoting strong adhesive interactions with IECs, have a functional role in balancing IL-8 mRNA expression induced by surface molecules such as lipoteichoic acid | Caco-2 cells | [ | |
| 37 | Cyclic dipeptide | Antiviral activity against influenza A (H3N2) | Madin-Darby canine kidney cells | [ | |
| 38 | Heat killed | Increase salivary IgA secretion in humans and prevent IFV infection | BALB/c mice | [ | |
| 39 | Aggregation-promoting factors (Apf) | Apf potentially confers properties that promote bile tolerance and interaction with the host epithelium and, hence, may contribute to the fitness and adaptation of | Caco-2 (ATCC HTB-37) epithelial cell | [ | |
| 40 | Heat inactivated | Decrease stress induce and increase in salivary cortisol level, increase in expression of stress-responsive microRNAs | Healthy students (21 males and 11 females) | [ | |
| 41 | ROS | Improves metabolic homeostasis and corrects stress-induced despair behaviors. ROS production in the gut could be used to treat psychiatric disorders | Mice model | [ | |
| 42 | LPS | NK33 and NK98 additively or synergistically prevented and alleviated anxiety and depression by alleviating gut dysbiosis through the suppression of the proteobacteria population and gut microbiota LPS production | Mice model | [ | |
| 43 | Heat killed | PS128 has the potential to serve as an anxiolytic agent to regulate the motor functions and the mood of the host, and the chronic PS128 ingestion causes an increase in locomotor behavior and a reduction in anxiety-like behaviors | Mice Model | [ | |
| 44 | Heat killed or live | Heat-killed PS23 reverses corticosterone-reduced dopamine levels. PS23 improves corticosterone-reduced hippocampal protein levels of MR, GR, and BDNF | Mouse model | [ | |
| 45 | Heat killed | Healthy female under exam stress | [ | ||
| 46 | SCFAs | Mice model | [ | ||
| 47 | Cell-free supernatants | Downregulate the TNF-α secretion and upregulate the anti-inflammatory IL-10 production. | HT-29 human mucus secreting adenocarcinoma cell line (ATCC HTB-38) | [ | |
| 48 | Mucus-binding protein (Mub) | Mub plays an important role in the host-microbial cross talk and possesses the potential for pathogen exclusion to a greater extent than mediated by | Caco-2 and HT-29 cell lines | [ | |
| 49 | Exopolysaccharides (EPS) | NPS and APS play unique roles in the immunomodulatory effect of | Porcine intestinal cultured cell line | [ | |
| 50 | Lactobacillus kefir | S-layer proteins | S-layer proteins from kefir lactobacilli to antagonize biological effects of bacterial toxins | [ |
Fig. 2Modulation of intestinal barrier integrity by various postbiotics (schematic illustration depicting the action of various postbiotic molecules affecting intestinal barrier functions) (red arrow representing the upregulation of various signaling pathways by various postbiotic molecules while blue arrow representing the downregulation of signaling pathways). AMPs, antimicrobial peptides; AP-1, activating protein; CSP, capsular polysaccharide; IECs, intestinal epithelial cells; HIF, hypoxia-inducible factor; GPCRs, G-protein-coupled receptors; AhRs, aryl hydrogen receptors; P75 and P40, cell wall–associated hydrolase; EGFR, epidermal growth factor receptor; PI3K, phosphatidylinositol-3-kinase; PXR, pregnane X receptor; APRIL, a proliferation-inducing ligand; Hsp72 and Hsp25, heat shock proteins; ZO-1, zona occludin,1; IPA, indole 3-propionic acid; TEER, transepithelial electrical resistance; TJPs, tight junction proteins; TLR, toll-like receptors
Fig. 3Modulation of innate and adaptive immunity by various postbiotics (schematic illustration depicting the action of various postbiotic molecules affecting innate and adaptive immunity) (red arrow representing the upregulation of various signaling pathways by various postbiotic molecules while blue arrow representing the downregulation of signaling pathways; green arrow representing the reduction of postbiotic molecules after binding of SARS-CoV-2 with ACE-2 receptor) ACE2, angiotensin-converting enzyme; BAT1, amino acid transporter; NOD, nucleotide-binding oligomerization domain2 (NOD-2); IDO, indoleamine 2,3-dioxygenase; NKT, natural killer T; NRP-neuropilin; mTOR, mammalian target of rapamycin; PKA, protein kinase A; HD-5, human defensin-5; GPRs, G-protein receptors; IL, interleukin; IFN, interferon; JAK/STAT, Janus kinase/signal transducers and activators of transcription; MCP-1, monocyte chemoattractant protein,1; G-CSF, granulocyte colony-stimulating factor; IP-10, interferon gamma-induced protein 10; MIP-1A, macrophage inflammatory protein,1; VDR, vitamin D receptor
Fig. 4Postbiotics in balancing hypothalamic–pituitary–adrenal axis and mental health during post-COVID regime (schematic illustration depicting the action of various postbiotic molecules affecting mental health) (red arrow representing the upregulation of various signaling pathways by various postbiotic molecules while blue arrow representing the downregulation of signaling pathways) BDNF, brain-derived neurotrophic factor; DA, dopamine; 5-HT, 5-hydroxytryptamine or serotonin; BZA, benzoic acids; dgk, diacylglycerol kinase; EPS, exopolysaccharide; GABA, gamma-Aminobutyric acid; GLP-1, glucagon-like peptide,1; Glu, glutamate or glutaminergic; HO, hydrogen peroxide; HPA, hypothalamic–pituitary–adrenal axis; IECs, intestinal epithelial cells; IDO, indoleamine 2,3-dioxygenase; IL-6, interleukin-6; KYN, kynurenine; NE, norepinephrine; ROS, reactive oxygen species; SCFA, short-chain fatty acid; Tph1, tryptophan hydroxylase 1; TRP, tryptophan
Fig. 5Proposed model for the development of precision postbiotics to be used in the management of COVID-19 pandemic